ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1768

Value Of Arthroscopic Partial Meniscectomy In Treatment Of Symptomatic Patients With Meniscal Tears and Knee Osteoarthritis: Is More Research Warranted?

Elena Losina1, A. David Paltiel2, Elizabeth Dervan1, Yan Dong1, Kurt P. Spindler3, Lisa A. Mandl4, Morgan Jones5, John Wright6 and Jeffrey N. Katz7, 1Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Yale School of Public Health, New Haven, CT, 3Vanderbilt University, Nashville, TN, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, 6Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, 7Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Meniscectomy and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research III: Healthcare Costs and Mortality in Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Arthroscopic partial meniscectomy (APM) is often offered to patients with symptomatic meniscal tear (MT). Recent trials in symptomatic patients with MT and knee OA (MT + OA) revealed similar pain relief in persons treated with APM and those treated with physical therapy (PT) and then referred for APM if pain persisted. We assessed expected costs and outcomes of alternative surgical and non-surgical strategies for patients with MT+OA. We examined the value of further research in this population and its likely impact on treatment decisions and their outcomes.

Methods: We used data from the Meniscal Tear in OA Research (MeTeOR) multicenter RCT (mean age 58, 76% Kellgren-Lawrence (KL) grade<3, 24% KL3) to estimate input parameters for a Markov state-transition computer simulation model. The model estimates long-term clinical and economic outcomes of management of MT+OA. We considered 3 strategies: 1) PT only, 2) APM, 3) PT with referral for APM, if PT did not relieve pain. We performed the analysis over a 10-year timeframe and considered short-term pain relief, subsequent pain onset (due to OA) and pain resolution. Transition probabilities were derived from MeTeOR and stratified by KL grade and time from treatment initiation. Pain relief 3 months after APM was 69% (95% CI: 59%-79%) among those with KL<3 and 51% (95% CI: 36%-66%) among those with KL3. Pain relief following APM among those who failed PT was worse (58% for KL<3 and 25% for KL3). Pain relief from PT alone was 49% (95% CI: 39%-58%) for KL<3 and 34% (95% CI 19%-50%) for KL3. Costs of PT ($680/3 month) and pain control ($215/quarter) were derived from MeTeOR and costs of APM ($2,800) from the Medicare Fee Schedule. We performed a probabilistic sensitivity analysis to examine the impact of parameter uncertainty on our finding. To estimate the value of further research, we assessed the expected value of partial perfect information (EVPPI), related to pain-based model parameters. We used willingness to pay (WTP) thresholds from $50k to $144K/QALY to denote programs as “cost-effective”.

Results: PT alone led to quality-adjusted life expectancy of 6.96 years with costs of $4,116. Delayed APM (in those who failed PT) led to 7.009 QALYs with costs of $8,130, yielding an incremental cost-effectiveness ratio (ICER) of $80,300/QALY. Immediate APM produced both higher costs ($9,556) and lower QALYs (7.008). In persons with KL<3, the estimated ICERs were $42,200/QALY for delayed APM and $106,400/QALY for immediate APM. In persons with KL3, neither APM-based strategy had favorable cost-effectiveness. Accounting for uncertainty in parameter estimates, in persons with KL<3, the probability of immediate APM being cost-effective ranged from 35% if WTP=$50K to 50% if WTP=$144K. The EVPPI that would result from reducing uncertainty in likelihood of pain relief and subsequent development and resolution of pain was estimated at $2,700/person.

Conclusion: APM-based strategies are unlikely to be cost-effective for MT+OA, even in those with less advanced OA. However, this conclusion is sensitive to assumptions regarding short- and long-term pain relief. Given the prevalence of this condition, more research on pain parameters is warranted.


Disclosure:

E. Losina,

JBJS,

9;

A. D. Paltiel,
None;

E. Dervan,
None;

Y. Dong,
None;

K. P. Spindler,

Smith & Nephew, Inc.,

9;

L. A. Mandl,

Boehringer Ingelheim,

2;

M. Jones,

Allergan Inc.,

5;

J. Wright,
None;

J. N. Katz,

OARSI,

6,

JBJS,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/value-of-arthroscopic-partial-meniscectomy-in-treatment-of-symptomatic-patients-with-meniscal-tears-and-knee-osteoarthritis-is-more-research-warranted/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology